Bill Dawson retired from Eli Lilly and Co in 1996 after 27 years service and established Bionet Ltd as a health care consultancy working at the interface between academia and industry. At Lilly, Bill was Research Director for 14 years and took 15 compounds into development, two of which reached the market. Latterly, he was Director of Technology Acquisition, Europe, for Lilly, and he continues to be a member of the ABPI Academic Liaison Working Group. Bill is Director of the University of Manchester Medicines Network, and a non-executive director of Proteome Sciencesplc, Antitope Ltd, and Pharmovation Ltd as well as a member of a number of corporate Scientific Advisory Boards. Professor Dawson qualified as a pharmacist, specialising in pharmacology, and his research interests are in immunopharmacology and the rational design, selection and progression of new medicines through optimal R&D programmes.